We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-15.65%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$215M
AUM Growth
-$26.2M
Cap. Flow
+$19.8M
Cap. Flow %
9.2%
Top 10 Hldgs %
74.42%
Holding
31
New
3
Increased
13
Reduced
8
Closed
6

Top Buys

1
AFMD
Affimed
AFMD
+$10.8M
2
AMRN
Amarin Corp
AMRN
+$8.5M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$7.86M
4
RZLT icon
Rezolute
RZLT
+$7.49M
5
CSTL icon
Castle Biosciences
CSTL
+$6.86M

Top Sells

1
ATRS
Antares Pharma, Inc.
ATRS
+$12.8M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$8.54M
3
EOLS icon
Evolus
EOLS
+$6.58M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$5.14M
5
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$2.24M

Sector Composition

1 Healthcare 95.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$44M 20.48%
6,298,348
-39,852
-0.6% -$311K
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$22M 10.23%
3,681,195
-1,003,209
-21% -$5.14M
XERS icon
3
Xeris Biopharma Holdings
XERS
$1.52B
$17.9M 8.35%
11,647,417
+3,723,361
+47% +$7.86M
ADMA icon
4
ADMA Biologics
ADMA
$2.02B
$13.9M 6.45%
7,000,000
-131,808
-2% -$259K
AMRN
5
Amarin Corp
AMRN
$292M
$13.2M 6.14%
442,688
+197,052
+80% +$8.5M
QDEL icon
6
QuidelOrtho
QDEL
$1.19B
$11.6M 5.42%
119,787
+57,996
+94% +$5.91M
RZLT icon
7
Rezolute
RZLT
$444M
$9.7M 4.51%
3,001,926
+2,253,224
+301% +$7.49M
OPTN
8
DELISTED
OptiNose
OPTN
$9.58M 4.46%
174,434
-20,660
-11% -$760K
URGN icon
9
UroGen Pharma
URGN
$1.96B
$9.1M 4.23%
1,111,050
+842,217
+313% +$5.78M
LGND icon
10
Ligand Pharmaceuticals
LGND
$6.08B
$8.94M 4.16%
160,691
+42,550
+36% +$2.41M
AFMD
11
DELISTED
Affimed
AFMD
$8.71M 4.05%
+314,377
New +$10.8M
APEN
12
DELISTED
Apollo Endosurgery, Inc.
APEN
$7.89M 3.67%
2,161,999
+468,165
+28% +$2.21M
OVID icon
13
Ovid Therapeutics
OVID
$455M
$7.5M 3.49%
3,487,928
-730,141
-17% -$1.76M
XGN icon
14
Exagen
XGN
$106M
$7.24M 3.37%
1,260,387
+139,347
+12% +$811K
CSTL icon
15
Castle Biosciences
CSTL
$733M
$6.48M 3.02%
+295,372
New +$6.86M
CFMS
16
DELISTED
Conformis, Inc. Common Stock
CFMS
$6.12M 2.85%
692,174
+919
+0.1% +$10.5K
DMAC icon
17
DiaMedica Therapeutics
DMAC
$393M
$2.38M 1.11%
1,176,344
-20,901
-2% -$48.8K
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
$1.88M 0.88%
251,235
+157,335
+168% +$1.11M
OPNT
19
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$1.83M 0.85%
+152,278
New +$2.46M
ATYR
20
aTyr Pharma
ATYR
$50M
$1.7M 0.79%
601,580
– –
MRNS
21
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.17M 0.55%
242,327
+185,580
+327% +$1.13M
XOMA
22
DELISTED
Xoma
XOMA
$1.02M 0.48%
45,910
+9,107
+25% +$187K
ANIP icon
23
ANI Pharmaceuticals
ANIP
$1.8B
$854K 0.4%
28,800
+2,740
+11% +$79K
SYBX
24
DELISTED
Synlogic
SYBX
$107K 0.05%
6,183
-64,759
-91% -$1.4M
CDTX
25
DELISTED
Cidara Therapeutics
CDTX
$102K 0.05%
10,422
-114,404
-92% -$1.41M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Stonepine Capital Management held 31 positions worth $215M, down 11% from $241M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Stonepine Capital Management deployed $19.8M of net new capital in Q2 2022, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was Affimed: 314,377 shares worth $8.71M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $5.14M trimmed.

  • Stonepine Capital Management's largest Q2 2022 buy was Affimed: 314,377 shares worth $8.71M.
  • Stonepine Capital Management added most to Amarin Corp in Q2 2022, an estimated $8.5M increase.
  • Stonepine Capital Management's biggest Q2 2022 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $5.14M.
  • Stonepine Capital Management fully exited Antares Pharma, Inc. in Q2 2022, selling an estimated $12.8M.
  • Stonepine Capital Management's ten largest holdings make up 74% of its $215M portfolio in Q2 2022.
  • Stonepine Capital Management opened 3 new positions and closed 6 in Q2 2022.
  • Stonepine Capital Management's portfolio value fell 11% quarter-over-quarter to $215M.

Based on Stonepine Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.